Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Ac-225 ErbB3 targeted radiotherapy

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Actinium, LG Chem

Drug class:

HER3 inhibitor, α radiation emission

Related drugs:

‹

lintuzumab-Ac225 (2)

lintuzumab-Ac225 (2)

›

ERBB3 expression	Renal Cell Carcinoma	ERBB3 expression	Renal Cell Carcinoma	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical AACR 2023 - 1 week (New D) Ac-225 ErbB3 targeted radiotherapy Sensitive : D AACR 2023 - 1wk	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical AACR 2023 - 1 week Ac-225 ErbB3 targeted radiotherapy Sensitive : D AACR 2023 - 1 week - (New D)
ERBB3 expression	Prostate Cancer	ERBB3 expression	Prostate Cancer	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical AACR 2023 - 1 week (New D) Ac-225 ErbB3 targeted radiotherapy Sensitive : D AACR 2023 - 1wk	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical AACR 2023 - 1 week Ac-225 ErbB3 targeted radiotherapy Sensitive : D AACR 2023 - 1 week - (New D)
ERBB3 expression	Colorectal Cancer	ERBB3 expression	Colorectal Cancer	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical AACR 2023 - 1 week (New D) Ac-225 ErbB3 targeted radiotherapy Sensitive : D AACR 2023 - 1wk	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical AACR 2023 - 1 week Ac-225 ErbB3 targeted radiotherapy Sensitive : D AACR 2023 - 1 week - (New D)
ERBB3 expression	Ovarian Cancer	ERBB3 expression	Ovarian Cancer	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical AACR 2023 - 1 week (New D) Ac-225 ErbB3 targeted radiotherapy Sensitive : D AACR 2023 - 1wk	Ac-225 ErbB3 targeted radiotherapy Sensitive: D – Preclinical AACR 2023 - 1 week Ac-225 ErbB3 targeted radiotherapy Sensitive : D AACR 2023 - 1 week - (New D)